BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34806651)

  • 21. Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion.
    Zarei M; Du H; Nassar AH; Yan RE; Giannikou K; Johnson SH; Lam HC; Henske EP; Wang Y; Zhang T; Asara J; Kwiatkowski DJ
    J Exp Med; 2019 Nov; 216(11):2635-2652. PubMed ID: 31506280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mTORC1-mediated downregulation of COX2 restrains tumor growth caused by TSC2 deficiency.
    Li H; Jin F; Jiang K; Ji S; Wang L; Ni Z; Chen X; Hu Z; Zhang H; Liu Y; Qin Y; Zha X
    Oncotarget; 2016 May; 7(19):28435-47. PubMed ID: 27078846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neural progenitors derived from Tuberous Sclerosis Complex patients exhibit attenuated PI3K/AKT signaling and delayed neuronal differentiation.
    Zucco AJ; Pozzo VD; Afinogenova A; Hart RP; Devinsky O; D'Arcangelo G
    Mol Cell Neurosci; 2018 Oct; 92():149-163. PubMed ID: 30144504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/- cells.
    Uhlmann EJ; Apicelli AJ; Baldwin RL; Burke SP; Bajenaru ML; Onda H; Kwiatkowski D; Gutmann DH
    Oncogene; 2002 Jun; 21(25):4050-9. PubMed ID: 12037687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tuberous sclerosis complex: From molecular biology to novel therapeutic approaches.
    Switon K; Kotulska K; Janusz-Kaminska A; Zmorzynska J; Jaworski J
    IUBMB Life; 2016 Dec; 68(12):955-962. PubMed ID: 27797139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779.
    Messina MP; Rauktys A; Lee L; Dabora SL
    BMC Pharmacol; 2007 Nov; 7():14. PubMed ID: 17986349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [
    Verwer EE; Kavanagh TR; Mischler WJ; Feng Y; Takahashi K; Wang S; Shoup TM; Neelamegam R; Yang J; Guehl NJ; Ran C; Massefski W; Cui Y; El-Chemaly S; Sadow PM; Oldham WM; Kijewski MF; El Fakhri G; Normandin MD; Priolo C
    Clin Cancer Res; 2018 Dec; 24(23):5925-5938. PubMed ID: 30054282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutational analysis of TSC1 and TSC2 in Japanese patients with tuberous sclerosis complex revealed higher incidence of TSC1 patients than previously reported.
    Niida Y; Wakisaka A; Tsuji T; Yamada H; Kuroda M; Mitani Y; Okumura A; Yokoi A
    J Hum Genet; 2013 Apr; 58(4):216-25. PubMed ID: 23389244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tsc2 mutation rather than Tsc1 mutation dominantly causes a social deficit in a mouse model of tuberous sclerosis complex.
    Kashii H; Kasai S; Sato A; Hagino Y; Nishito Y; Kobayashi T; Hino O; Mizuguchi M; Ikeda K
    Hum Genomics; 2023 Feb; 17(1):4. PubMed ID: 36732866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complex Neurological Phenotype in Mutant Mice Lacking Tsc2 in Excitatory Neurons of the Developing Forebrain(123).
    Crowell B; Lee GH; Nikolaeva I; Dal Pozzo V; D'Arcangelo G
    eNeuro; 2015; 2(6):. PubMed ID: 26693177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The analysis of mutations and exon deletions at TSC2 gene in angiomyolipomas associated with tuberous sclerosis complex.
    Yang HM; Choi HJ; Hong DP; Joo SY; Lee NE; Song JY; Choi YL; Lee J; Choi D; Kim B; Park HJ; Park JB; Kim SJ
    Exp Mol Pathol; 2014 Dec; 97(3):440-4. PubMed ID: 25281918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Finding a cure for tuberous sclerosis complex: From genetics through to targeted drug therapies.
    McEneaney LJ; Tee AR
    Adv Genet; 2019; 103():91-118. PubMed ID: 30904097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.
    Lo AS; Ma Q; Liu DL; Junghans RP
    Clin Cancer Res; 2010 May; 16(10):2769-80. PubMed ID: 20460472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
    Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
    J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abnormal glycogen storage in tuberous sclerosis complex caused by impairment of mTORC1-dependent and -independent signaling pathways.
    Pal R; Xiong Y; Sardiello M
    Proc Natl Acad Sci U S A; 2019 Feb; 116(8):2977-2986. PubMed ID: 30728291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
    Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
    Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational analysis of TSC1 and TSC2 genes in Tuberous Sclerosis Complex patients from Greece.
    Avgeris S; Fostira F; Vagena A; Ninios Y; Delimitsou A; Vodicka R; Vrtel R; Youroukos S; Stravopodis DJ; Vlassi M; Astrinidis A; Yannoukakos D; Voutsinas GE
    Sci Rep; 2017 Dec; 7(1):16697. PubMed ID: 29196670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for population variation in TSC1 and TSC2 gene expression.
    Jentarra GM; Rice SG; Olfers S; Saffen D; Narayanan V
    BMC Med Genet; 2011 Feb; 12():29. PubMed ID: 21345208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish.
    Kim SH; Kowalski ML; Carson RP; Bridges LR; Ess KC
    Dis Model Mech; 2013 Jul; 6(4):925-33. PubMed ID: 23580196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Targeting of DGKA-Mediated Macropinocytosis Leads to Phospholipid Reprogramming in Tuberous Sclerosis Complex.
    Kovalenko A; Sanin A; Kosmas K; Zhang L; Wang J; Akl EW; Giannikou K; Probst CK; Hougard TR; Rue RW; Krymskaya VP; Asara JM; Lam HC; Kwiatkowski DJ; Henske EP; Filippakis H
    Cancer Res; 2021 Apr; 81(8):2086-2100. PubMed ID: 33593821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.